摘要
目的:探讨摩罗丹联合雷贝拉唑治疗老年慢性萎缩性胃炎的效果。方法:选择2022年2月—2023年2月于蕲春县人民医院接受治疗的90例老年慢性萎缩性胃炎患者作为研究对象,按照信封法将其分为研究组和参比组,各45例。参比组实施以雷贝拉唑为主的常规治疗,研究组在参比组基础上联合摩罗丹治疗,比较两组胃肠激素、血清炎症因子、临床疗效及不良反应。结果:治疗后,两组胃泌素(GAS)、胃动素(MTL)及血清炎症因子水平较治疗前改善,其中研究组GAS及血清白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)水平低于参比组,而MTL高于参比组,差异有统计学意义(P<0.05);研究组临床总有效率为95.56%,高于参比组的82.22%,研究组不良反应发生率为8.89%,低于参比组的24.44%,差异有统计学意义(P<0.05)。结论:老年慢性萎缩性胃炎患者实施摩罗丹与雷贝拉唑联合治疗,能显著改善血清胃肠激素、炎症因子水平,进而提高临床疗效,控制不良反应。
Objective:To explore the effect of Moluodan combined with Rabeprazole in the treatment of elderly chronic atrophic gastritis.Method:A total of 90 elderly patients with chronic atrophic gastritis who treated in Qichun County People's Hospital from February 2022 to February 2023 were selected as the research objects,they were divided into the study group and the reference group according to the envelope method,with 45 cases in each group.The reference group was treated with Rabeprazole-based conventional therapy,and the study group was treated with Moluodan on the basis of the reference group.The gastrointestinal hormones,serum inflammatory factors,clinical efficacy and adverse reactions were compared between two groups.Result:After treatment,the levels of gastrin(GAS),motilin(MTL)and serum inflammatory factors in two groups were improved compared with those before treatment,the levels of GAS,serum interleukin-6(IL-6),tumor necrosis factor-α(TNF-α)and high-sensitivity C-reactive protein(hs-CRP)in the study group were lower than those in the reference group,while the level of MTL was higher than that in the reference group,and the differences were statistically significant(P<0.05);the total clinical effective rate of the study group was 95.56%,which was higher than 82.22%of the reference group,the incidence of adverse reactions in the study group was 8.89%,which was lower than 24.44%in the reference group,the differences were statistically significant(P<0.05).Conclusion:The combined treatment of Moluodan and Rabeprazole for elderly patients with chronic atrophic gastritis can significantly improve the levels of serum gastrointestinal hormones and inflammatory factors,thereby improving clinical efficacy and controlling adverse reactions.
作者
陈洪
CHEN Hong(:Qichun County People's Hospital,Qichun 435300,China)
出处
《中外医学研究》
2024年第29期138-141,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
